Donald Ingle, MD
Family Medicine · Arlington, TXNPI 1972563492
Payments from drug & device makers
Across 237 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$856
- Lilly USA, LLC$464
- Boehringer Ingelheim$330
- GSK$325
- Pfizer$259
- Bayer$201
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,923100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $856 |
| Lilly USA, LLC | 28 | $464 |
| Boehringer Ingelheim | 18 | $330 |
| GSK | 20 | $325 |
| Pfizer | 14 | $259 |
| Bayer | 12 | $201 |
| Novo Nordisk | 9 | $149 |
| Astellas Pharma US Inc | 9 | $136 |
| Tris Pharma Inc | 1 | $122 |
| Johnson & Johnson | 6 | $114 |
| AstraZeneca | 7 | $99 |
| Dexcom, Inc. | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Amgen | 4 | $64 |
| Abbott | 4 | $64 |
| Merck | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 5 | $60 |
| Exact Sciences | 3 | $60 |
| Novartis | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Boston Scientific | 1 | $26 |
| Insulet Corporation | 2 | $25 |
| Seqirus USA Inc | 1 | $25 |
| Eisai Inc. | 1 | $21 |
| Biotronik NRO, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Medtronic | 1 | $19 |
| Halozyme Inc | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Merz North America, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$122
- Quillivant$122
- Quillichew ER$122
How this compares
$3,923 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $130,861 |
| EliquisApixaban | 63 | $68,328 |
| OzempicSemaglutide | 38 | $47,055 |
| TrulicityDulaglutide | 36 | $43,639 |
| MounjaroTirzepatide | 32 | $38,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $29,877 |
| MyrbetriqMirabegron | 25 | $29,641 |
| RybelsusSemaglutide | 15 | $29,624 |
| JanuviaSitagliptin Phosphate | 25 | $23,043 |
| XareltoRivaroxaban | 20 | $20,661 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $16,210 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $13,507 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $8,470 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,897 |
| Repatha SureclickEvolocumab | 11 | $6,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $330 | $144,368125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $464 | $82,49768 claims |
| Novo NordiskOzempic, Rybelsus | $149 | $76,67953 claims |
| PfizerEliquis, Paxlovid | $259 | $69,75781 claims |
| GSKTrelegy Ellipta | $325 | $29,87733 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $29,64125 claims |
| MerckJanuvia | $62 | $23,04325 claims |
| Johnson & JohnsonXarelto | $114 | $20,66120 claims |
| AstraZenecaSymbicort | $99 | $16,21053 claims |
| AbbVieNamzaric, Synthroid | $856 | $9,89036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.